A Pill to Prevent HIV Infection on Its Way


A Pill to Prevent HIV Infection on Its WayA panel of US Federal advisers appear to be overwhelmed at the very first drug that has revealed to battle against HIV infection. The outcome is near to being approved as a measure that has finally got the world close to ending the 30-year battle against the illness.

The Food and Drug Administration advisory panel has recommended approval to a daily consumption of Truvada for healthy individuals in danger of contracting the HIV. The list of healthy individuals in danger of contracting the virus includes bisexual men, heterosexuals and gays with a HIV-positive spouse.

Although, the FDA needs to follow the panel’s guidance, it does not have to in proceeding with the recommendation approval. The panel and the FDA will come to a final conclusion by 15th June 2012. Truvada has been marketed by Gilead Sciences Inc. since 2004 to deal with individuals infected with the virus.

Travuda consists of 2 older HIV medications named Viread and Emtriva. Until today, physicians have only prescribed it as a drug cocktail, that represses the virus. Although, the panelists were satisfied with the efficacy of this medication to protect against the spread and development of HIV, the 12-hour meeting brought into light other issues which were created by the drug.

Some questions that were highlighted include that of if reduced danger of HIV would mean a reduced usage of condom since condom is considered and in fact, is the most trusted defence against HIV. The specialists also challenged the power of the drug in women, who have demonstrated a far lesser rate of protection. The panelists had difficulty figuring out how they would ensure that the patients take a pill every day.

Once the clinical trials were assessed, it had been found that patients who didn’t take the medication frequently were not protected. The panelists are looking ahead to see whether it works when it is taken and if the possible risks outweigh the advantages.


Please enter your comment!
Please enter your name here